These peptides, along with a number of highly specific HCC MHC-I-bound tumor peptides, contributed to the formation of a peptide cocktail to be used as the first multi-epitope, multi-target, and multi-allele cancer vaccine against HCC aimed at stimulating both CD4+ and CD8+ T cells. This evidence concerns the gene CD4 and hepatocellular carcinoma.